Understanding how a flexible cell type affects lung cancer
Official title: Determining the role and function of a high plasticity cell state in lung adenocarcinoma
Funded at Sloan-Kettering Inst Can Research · NIH-10888274 · Data updated 2026-11-12
This study is looking at how certain flexible cells in lung adenocarcinoma, a type of lung cancer, help the tumors grow and resist treatments, with the hope of finding ways to improve outcomes for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 22, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $249,526 |
| NIH project number | 5K08CA267072-03 |
| Project ID | NIH-10888274 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lung adenocarcinoma, particularly those experiencing treatment resistance.
✕Less likely to help
Patients with other types of lung cancer or those who are not currently undergoing treatment may not benefit from this research.
What this research studies
This research investigates the role of a specific high plasticity cell state in lung adenocarcinoma, a common and aggressive form of lung cancer. By analyzing single cell transcriptomes from mouse models and human tumors, the researchers aim to understand how this cell state contributes to tumor growth and resistance to treatments. The study involves profiling these cells at various stages of cancer progression and examining their behavior under therapeutic stress. The goal is to uncover the mechanisms behind tumor plasticity and its impact on patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for overcoming treatment resistance in lung cancer patients.
How similar studies have gone: Previous research has shown that targeting tumor plasticity can improve treatment outcomes, suggesting that this approach may hold promise.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Chan, Jason Earl — Sloan-Kettering Inst Can Research
- Study coordinator: Chan, Jason Earl
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.